Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists
The CXCL12-CXCR4 signaling axis in malignant tumor biology has increased in importance, and these peptides are implicated in tumor growth, invasion and metastasis. The aim of our study was to examine the important role of the axis in pancreatic cancer (PaCa) cells' relationship with stromal cel...
Gespeichert in:
| Veröffentlicht in: | BMC cancer 2016-05, Vol.16 (308), p.305, Article 305 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 308 |
| container_start_page | 305 |
| container_title | BMC cancer |
| container_volume | 16 |
| creator | Morimoto, Mamoru Matsuo, Yoichi Koide, Shuji Tsuboi, Ken Shamoto, Tomoya Sato, Takafumi Saito, Kenta Takahashi, Hiroki Takeyama, Hiromitsu |
| description | The CXCL12-CXCR4 signaling axis in malignant tumor biology has increased in importance, and these peptides are implicated in tumor growth, invasion and metastasis. The aim of our study was to examine the important role of the axis in pancreatic cancer (PaCa) cells' relationship with stromal cells in gemcitabine-resistant (GEM-R) tumors and to confirm the effectiveness of CXCR4 antagonists for the treatment of GEM-R PaCa cells.
We established two GEM-R PaCa cell lines using MIA PaCa-2 and AsPC-1 cells. The expression of CXCR4 mRNA in PaCa cells and the expression of CXCL12 mRNA in fibroblasts were examined by reverse transcription polymerase chain reaction (RT-PCR). The expression of CXCR4 protein in PaCa cells was examined by immunosorbent assay (ELISA) and immunocytochemistry. Using Matrigel invasion assays and animal studies, we then examined the effects of two CXCR4 antagonists, AMD11070 and KRH3955, on the invasiveness and tumorigenicity of GEM-R PaCa cells stimulated by CXCL12.
We found that the expression of CXCR4 in GEM-R PaCa cells was significantly enhanced by GEM but not in normal GEM-sensitive (GEM-S) PaCa cells. In RT-PCR and ELISA assays, the production and secretion of CXCL12 from fibroblasts was significantly enhanced by co-culturing with GEM-R PaCa cells treated with GEM. In Matrigel invasion assays, the invasiveness of GEM-R PaCa cells treated with GEM was significantly activated by fibroblast-derived CXCL12 and was significantly inhibited by CXCR4 antagonists, AMD11070 and KRH3955. In vivo, the tumorigenicity of GEM-R PaCa cells was activated by GEM, and it was significantly inhibited by the addition with CXCR4 antagonists.
Our findings demonstrate that the CXCL12-CXCR4 signaling axis plays an important role in PaCa cells' resistance to GEM. CXCR4 expression was significantly enhanced by the exposure to GEM in GEM-R PaCa cells but not in GEM-S PaCa cells. Furthermore, CXCR4 antagonists can inhibit the growth and invasion of GEM-R PaCa cells. These agents may be useful as second-line chemotherapy for GEM-R PaCa in the future. |
| doi_str_mv | 10.1186/s12885-016-2340-z |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4866076</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A452301170</galeid><sourcerecordid>A452301170</sourcerecordid><originalsourceid>FETCH-LOGICAL-c597t-b5d44c36756c287e3b134e7e75925e4b5ca7c1326551891c5004da86dfd5d5343</originalsourceid><addsrcrecordid>eNptkl9r1TAYxoM43B_9AN5IQBC86JY0SdPjxWAcpg4ODDYF70Kavm0jbXJsUpm73Rc39cxxCiMXb3jze57wJg9Cbyk5pbQszgLNy1JkhBZZzjjJ7l-gI8olzXJO5Mu9_SE6DuEnIVSWpHyFDnNJpeCSHaGHS9dpZ2AAF7FvcOwAr3-sNzQ_S-WGY31nA64nwNFjbX5NNthovZvZFgZjo66sAzxCsCHOTtg6vE2bEXS0Bpu5N37C0DRg_l3x6Ouibr1LovAaHTS6D_DmsZ6g758vv62_ZpvrL1fri01mxErGrBI154YVUhQmLyWwijIOEqRY5QJ4JYyWhrK8EIKWK2oEIbzWZVE3tagF4-wEne98t1M1QG3SyKPu1Xa0gx7_KK-tWp4426nW_1a8LAoii2TwfmfQ6h6UdY1PmBlsMOqCi5wRSiVJ1OkzVFo1DNZ4B41N_YXg40KQmAh3sdVTCOrq9mbJfthjO9B97ILvp_lPwhKkO9CMPoQRmqc5KVFzetQuPSqlR83pUfdJ827_gZ4U_-PC_gKQ2b4U</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>EZB-FREE-00999 freely available EZB journals</source><source>PubMed Central</source><source>SpringerLink Journals - AutoHoldings</source><source>PubMed Central Open Access</source><source>Springer Nature OA Free Journals</source><creator>Morimoto, Mamoru ; Matsuo, Yoichi ; Koide, Shuji ; Tsuboi, Ken ; Shamoto, Tomoya ; Sato, Takafumi ; Saito, Kenta ; Takahashi, Hiroki ; Takeyama, Hiromitsu</creator><creatorcontrib>Morimoto, Mamoru ; Matsuo, Yoichi ; Koide, Shuji ; Tsuboi, Ken ; Shamoto, Tomoya ; Sato, Takafumi ; Saito, Kenta ; Takahashi, Hiroki ; Takeyama, Hiromitsu</creatorcontrib><description>The CXCL12-CXCR4 signaling axis in malignant tumor biology has increased in importance, and these peptides are implicated in tumor growth, invasion and metastasis. The aim of our study was to examine the important role of the axis in pancreatic cancer (PaCa) cells' relationship with stromal cells in gemcitabine-resistant (GEM-R) tumors and to confirm the effectiveness of CXCR4 antagonists for the treatment of GEM-R PaCa cells.
We established two GEM-R PaCa cell lines using MIA PaCa-2 and AsPC-1 cells. The expression of CXCR4 mRNA in PaCa cells and the expression of CXCL12 mRNA in fibroblasts were examined by reverse transcription polymerase chain reaction (RT-PCR). The expression of CXCR4 protein in PaCa cells was examined by immunosorbent assay (ELISA) and immunocytochemistry. Using Matrigel invasion assays and animal studies, we then examined the effects of two CXCR4 antagonists, AMD11070 and KRH3955, on the invasiveness and tumorigenicity of GEM-R PaCa cells stimulated by CXCL12.
We found that the expression of CXCR4 in GEM-R PaCa cells was significantly enhanced by GEM but not in normal GEM-sensitive (GEM-S) PaCa cells. In RT-PCR and ELISA assays, the production and secretion of CXCL12 from fibroblasts was significantly enhanced by co-culturing with GEM-R PaCa cells treated with GEM. In Matrigel invasion assays, the invasiveness of GEM-R PaCa cells treated with GEM was significantly activated by fibroblast-derived CXCL12 and was significantly inhibited by CXCR4 antagonists, AMD11070 and KRH3955. In vivo, the tumorigenicity of GEM-R PaCa cells was activated by GEM, and it was significantly inhibited by the addition with CXCR4 antagonists.
Our findings demonstrate that the CXCL12-CXCR4 signaling axis plays an important role in PaCa cells' resistance to GEM. CXCR4 expression was significantly enhanced by the exposure to GEM in GEM-R PaCa cells but not in GEM-S PaCa cells. Furthermore, CXCR4 antagonists can inhibit the growth and invasion of GEM-R PaCa cells. These agents may be useful as second-line chemotherapy for GEM-R PaCa in the future.</description><identifier>ISSN: 1471-2407</identifier><identifier>EISSN: 1471-2407</identifier><identifier>DOI: 10.1186/s12885-016-2340-z</identifier><identifier>PMID: 27175473</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Animals ; Antimetabolites, Antineoplastic - pharmacology ; Apoptosis - drug effects ; Cancer ; Care and treatment ; Cell Proliferation - drug effects ; Chemokine CXCL12 - metabolism ; Chemotherapy ; Complications and side effects ; Deoxycytidine - analogs & derivatives ; Deoxycytidine - pharmacology ; Female ; Fibroblasts - drug effects ; Fibroblasts - metabolism ; Fibroblasts - pathology ; Health aspects ; Heterocyclic Compounds, 1-Ring - pharmacology ; Humans ; Influence ; Mice ; Mice, Inbred BALB C ; Mice, Nude ; Pancreatic cancer ; Pancreatic Neoplasms - drug therapy ; Pancreatic Neoplasms - metabolism ; Pancreatic Neoplasms - pathology ; Receptors, CXCR4 - antagonists & inhibitors ; Receptors, CXCR4 - metabolism ; Stromal Cells - drug effects ; Stromal Cells - metabolism ; Stromal Cells - pathology ; Transforming growth factors ; Tumor Cells, Cultured ; Xenograft Model Antitumor Assays</subject><ispartof>BMC cancer, 2016-05, Vol.16 (308), p.305, Article 305</ispartof><rights>COPYRIGHT 2016 BioMed Central Ltd.</rights><rights>Morimoto et al. 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c597t-b5d44c36756c287e3b134e7e75925e4b5ca7c1326551891c5004da86dfd5d5343</citedby><cites>FETCH-LOGICAL-c597t-b5d44c36756c287e3b134e7e75925e4b5ca7c1326551891c5004da86dfd5d5343</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4866076/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4866076/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27175473$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Morimoto, Mamoru</creatorcontrib><creatorcontrib>Matsuo, Yoichi</creatorcontrib><creatorcontrib>Koide, Shuji</creatorcontrib><creatorcontrib>Tsuboi, Ken</creatorcontrib><creatorcontrib>Shamoto, Tomoya</creatorcontrib><creatorcontrib>Sato, Takafumi</creatorcontrib><creatorcontrib>Saito, Kenta</creatorcontrib><creatorcontrib>Takahashi, Hiroki</creatorcontrib><creatorcontrib>Takeyama, Hiromitsu</creatorcontrib><title>Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists</title><title>BMC cancer</title><addtitle>BMC Cancer</addtitle><description>The CXCL12-CXCR4 signaling axis in malignant tumor biology has increased in importance, and these peptides are implicated in tumor growth, invasion and metastasis. The aim of our study was to examine the important role of the axis in pancreatic cancer (PaCa) cells' relationship with stromal cells in gemcitabine-resistant (GEM-R) tumors and to confirm the effectiveness of CXCR4 antagonists for the treatment of GEM-R PaCa cells.
We established two GEM-R PaCa cell lines using MIA PaCa-2 and AsPC-1 cells. The expression of CXCR4 mRNA in PaCa cells and the expression of CXCL12 mRNA in fibroblasts were examined by reverse transcription polymerase chain reaction (RT-PCR). The expression of CXCR4 protein in PaCa cells was examined by immunosorbent assay (ELISA) and immunocytochemistry. Using Matrigel invasion assays and animal studies, we then examined the effects of two CXCR4 antagonists, AMD11070 and KRH3955, on the invasiveness and tumorigenicity of GEM-R PaCa cells stimulated by CXCL12.
We found that the expression of CXCR4 in GEM-R PaCa cells was significantly enhanced by GEM but not in normal GEM-sensitive (GEM-S) PaCa cells. In RT-PCR and ELISA assays, the production and secretion of CXCL12 from fibroblasts was significantly enhanced by co-culturing with GEM-R PaCa cells treated with GEM. In Matrigel invasion assays, the invasiveness of GEM-R PaCa cells treated with GEM was significantly activated by fibroblast-derived CXCL12 and was significantly inhibited by CXCR4 antagonists, AMD11070 and KRH3955. In vivo, the tumorigenicity of GEM-R PaCa cells was activated by GEM, and it was significantly inhibited by the addition with CXCR4 antagonists.
Our findings demonstrate that the CXCL12-CXCR4 signaling axis plays an important role in PaCa cells' resistance to GEM. CXCR4 expression was significantly enhanced by the exposure to GEM in GEM-R PaCa cells but not in GEM-S PaCa cells. Furthermore, CXCR4 antagonists can inhibit the growth and invasion of GEM-R PaCa cells. These agents may be useful as second-line chemotherapy for GEM-R PaCa in the future.</description><subject>Animals</subject><subject>Antimetabolites, Antineoplastic - pharmacology</subject><subject>Apoptosis - drug effects</subject><subject>Cancer</subject><subject>Care and treatment</subject><subject>Cell Proliferation - drug effects</subject><subject>Chemokine CXCL12 - metabolism</subject><subject>Chemotherapy</subject><subject>Complications and side effects</subject><subject>Deoxycytidine - analogs & derivatives</subject><subject>Deoxycytidine - pharmacology</subject><subject>Female</subject><subject>Fibroblasts - drug effects</subject><subject>Fibroblasts - metabolism</subject><subject>Fibroblasts - pathology</subject><subject>Health aspects</subject><subject>Heterocyclic Compounds, 1-Ring - pharmacology</subject><subject>Humans</subject><subject>Influence</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Mice, Nude</subject><subject>Pancreatic cancer</subject><subject>Pancreatic Neoplasms - drug therapy</subject><subject>Pancreatic Neoplasms - metabolism</subject><subject>Pancreatic Neoplasms - pathology</subject><subject>Receptors, CXCR4 - antagonists & inhibitors</subject><subject>Receptors, CXCR4 - metabolism</subject><subject>Stromal Cells - drug effects</subject><subject>Stromal Cells - metabolism</subject><subject>Stromal Cells - pathology</subject><subject>Transforming growth factors</subject><subject>Tumor Cells, Cultured</subject><subject>Xenograft Model Antitumor Assays</subject><issn>1471-2407</issn><issn>1471-2407</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNptkl9r1TAYxoM43B_9AN5IQBC86JY0SdPjxWAcpg4ODDYF70Kavm0jbXJsUpm73Rc39cxxCiMXb3jze57wJg9Cbyk5pbQszgLNy1JkhBZZzjjJ7l-gI8olzXJO5Mu9_SE6DuEnIVSWpHyFDnNJpeCSHaGHS9dpZ2AAF7FvcOwAr3-sNzQ_S-WGY31nA64nwNFjbX5NNthovZvZFgZjo66sAzxCsCHOTtg6vE2bEXS0Bpu5N37C0DRg_l3x6Ouibr1LovAaHTS6D_DmsZ6g758vv62_ZpvrL1fri01mxErGrBI154YVUhQmLyWwijIOEqRY5QJ4JYyWhrK8EIKWK2oEIbzWZVE3tagF4-wEne98t1M1QG3SyKPu1Xa0gx7_KK-tWp4426nW_1a8LAoii2TwfmfQ6h6UdY1PmBlsMOqCi5wRSiVJ1OkzVFo1DNZ4B41N_YXg40KQmAh3sdVTCOrq9mbJfthjO9B97ILvp_lPwhKkO9CMPoQRmqc5KVFzetQuPSqlR83pUfdJ827_gZ4U_-PC_gKQ2b4U</recordid><startdate>20160512</startdate><enddate>20160512</enddate><creator>Morimoto, Mamoru</creator><creator>Matsuo, Yoichi</creator><creator>Koide, Shuji</creator><creator>Tsuboi, Ken</creator><creator>Shamoto, Tomoya</creator><creator>Sato, Takafumi</creator><creator>Saito, Kenta</creator><creator>Takahashi, Hiroki</creator><creator>Takeyama, Hiromitsu</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>ISR</scope><scope>5PM</scope></search><sort><creationdate>20160512</creationdate><title>Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists</title><author>Morimoto, Mamoru ; Matsuo, Yoichi ; Koide, Shuji ; Tsuboi, Ken ; Shamoto, Tomoya ; Sato, Takafumi ; Saito, Kenta ; Takahashi, Hiroki ; Takeyama, Hiromitsu</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c597t-b5d44c36756c287e3b134e7e75925e4b5ca7c1326551891c5004da86dfd5d5343</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Animals</topic><topic>Antimetabolites, Antineoplastic - pharmacology</topic><topic>Apoptosis - drug effects</topic><topic>Cancer</topic><topic>Care and treatment</topic><topic>Cell Proliferation - drug effects</topic><topic>Chemokine CXCL12 - metabolism</topic><topic>Chemotherapy</topic><topic>Complications and side effects</topic><topic>Deoxycytidine - analogs & derivatives</topic><topic>Deoxycytidine - pharmacology</topic><topic>Female</topic><topic>Fibroblasts - drug effects</topic><topic>Fibroblasts - metabolism</topic><topic>Fibroblasts - pathology</topic><topic>Health aspects</topic><topic>Heterocyclic Compounds, 1-Ring - pharmacology</topic><topic>Humans</topic><topic>Influence</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Mice, Nude</topic><topic>Pancreatic cancer</topic><topic>Pancreatic Neoplasms - drug therapy</topic><topic>Pancreatic Neoplasms - metabolism</topic><topic>Pancreatic Neoplasms - pathology</topic><topic>Receptors, CXCR4 - antagonists & inhibitors</topic><topic>Receptors, CXCR4 - metabolism</topic><topic>Stromal Cells - drug effects</topic><topic>Stromal Cells - metabolism</topic><topic>Stromal Cells - pathology</topic><topic>Transforming growth factors</topic><topic>Tumor Cells, Cultured</topic><topic>Xenograft Model Antitumor Assays</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Morimoto, Mamoru</creatorcontrib><creatorcontrib>Matsuo, Yoichi</creatorcontrib><creatorcontrib>Koide, Shuji</creatorcontrib><creatorcontrib>Tsuboi, Ken</creatorcontrib><creatorcontrib>Shamoto, Tomoya</creatorcontrib><creatorcontrib>Sato, Takafumi</creatorcontrib><creatorcontrib>Saito, Kenta</creatorcontrib><creatorcontrib>Takahashi, Hiroki</creatorcontrib><creatorcontrib>Takeyama, Hiromitsu</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Science</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>BMC cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Morimoto, Mamoru</au><au>Matsuo, Yoichi</au><au>Koide, Shuji</au><au>Tsuboi, Ken</au><au>Shamoto, Tomoya</au><au>Sato, Takafumi</au><au>Saito, Kenta</au><au>Takahashi, Hiroki</au><au>Takeyama, Hiromitsu</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists</atitle><jtitle>BMC cancer</jtitle><addtitle>BMC Cancer</addtitle><date>2016-05-12</date><risdate>2016</risdate><volume>16</volume><issue>308</issue><spage>305</spage><pages>305-</pages><artnum>305</artnum><issn>1471-2407</issn><eissn>1471-2407</eissn><abstract>The CXCL12-CXCR4 signaling axis in malignant tumor biology has increased in importance, and these peptides are implicated in tumor growth, invasion and metastasis. The aim of our study was to examine the important role of the axis in pancreatic cancer (PaCa) cells' relationship with stromal cells in gemcitabine-resistant (GEM-R) tumors and to confirm the effectiveness of CXCR4 antagonists for the treatment of GEM-R PaCa cells.
We established two GEM-R PaCa cell lines using MIA PaCa-2 and AsPC-1 cells. The expression of CXCR4 mRNA in PaCa cells and the expression of CXCL12 mRNA in fibroblasts were examined by reverse transcription polymerase chain reaction (RT-PCR). The expression of CXCR4 protein in PaCa cells was examined by immunosorbent assay (ELISA) and immunocytochemistry. Using Matrigel invasion assays and animal studies, we then examined the effects of two CXCR4 antagonists, AMD11070 and KRH3955, on the invasiveness and tumorigenicity of GEM-R PaCa cells stimulated by CXCL12.
We found that the expression of CXCR4 in GEM-R PaCa cells was significantly enhanced by GEM but not in normal GEM-sensitive (GEM-S) PaCa cells. In RT-PCR and ELISA assays, the production and secretion of CXCL12 from fibroblasts was significantly enhanced by co-culturing with GEM-R PaCa cells treated with GEM. In Matrigel invasion assays, the invasiveness of GEM-R PaCa cells treated with GEM was significantly activated by fibroblast-derived CXCL12 and was significantly inhibited by CXCR4 antagonists, AMD11070 and KRH3955. In vivo, the tumorigenicity of GEM-R PaCa cells was activated by GEM, and it was significantly inhibited by the addition with CXCR4 antagonists.
Our findings demonstrate that the CXCL12-CXCR4 signaling axis plays an important role in PaCa cells' resistance to GEM. CXCR4 expression was significantly enhanced by the exposure to GEM in GEM-R PaCa cells but not in GEM-S PaCa cells. Furthermore, CXCR4 antagonists can inhibit the growth and invasion of GEM-R PaCa cells. These agents may be useful as second-line chemotherapy for GEM-R PaCa in the future.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>27175473</pmid><doi>10.1186/s12885-016-2340-z</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1471-2407 |
| ispartof | BMC cancer, 2016-05, Vol.16 (308), p.305, Article 305 |
| issn | 1471-2407 1471-2407 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4866076 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; EZB-FREE-00999 freely available EZB journals; PubMed Central; SpringerLink Journals - AutoHoldings; PubMed Central Open Access; Springer Nature OA Free Journals |
| subjects | Animals Antimetabolites, Antineoplastic - pharmacology Apoptosis - drug effects Cancer Care and treatment Cell Proliferation - drug effects Chemokine CXCL12 - metabolism Chemotherapy Complications and side effects Deoxycytidine - analogs & derivatives Deoxycytidine - pharmacology Female Fibroblasts - drug effects Fibroblasts - metabolism Fibroblasts - pathology Health aspects Heterocyclic Compounds, 1-Ring - pharmacology Humans Influence Mice Mice, Inbred BALB C Mice, Nude Pancreatic cancer Pancreatic Neoplasms - drug therapy Pancreatic Neoplasms - metabolism Pancreatic Neoplasms - pathology Receptors, CXCR4 - antagonists & inhibitors Receptors, CXCR4 - metabolism Stromal Cells - drug effects Stromal Cells - metabolism Stromal Cells - pathology Transforming growth factors Tumor Cells, Cultured Xenograft Model Antitumor Assays |
| title | Enhancement of the CXCL12/CXCR4 axis due to acquisition of gemcitabine resistance in pancreatic cancer: effect of CXCR4 antagonists |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T09%3A25%3A12IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Enhancement%20of%20the%20CXCL12/CXCR4%20axis%20due%20to%20acquisition%20of%20gemcitabine%20resistance%20in%20pancreatic%20cancer:%20effect%20of%20CXCR4%20antagonists&rft.jtitle=BMC%20cancer&rft.au=Morimoto,%20Mamoru&rft.date=2016-05-12&rft.volume=16&rft.issue=308&rft.spage=305&rft.pages=305-&rft.artnum=305&rft.issn=1471-2407&rft.eissn=1471-2407&rft_id=info:doi/10.1186/s12885-016-2340-z&rft_dat=%3Cgale_pubme%3EA452301170%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/27175473&rft_galeid=A452301170&rfr_iscdi=true |